Enliven Therapeutics, Inc. financial data

Symbol
ELVN on Nasdaq
Location
Boulder, CO
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2662% % 97%
Debt-to-equity 3.9% % -50%
Return On Equity -25% % 16%
Return On Assets -24% % 12%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59,347,317 shares 21%
Common Stock, Shares, Outstanding 59,261,286 shares 25%
Entity Public Float $683,800,000 USD 79%
Common Stock, Value, Issued $59,000 USD 26%
Weighted Average Number of Shares Outstanding, Basic 62,093,795 shares 29%
Weighted Average Number of Shares Outstanding, Diluted 62,093,795 shares 29%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $85,335,000 USD 9.5%
General and Administrative Expense $26,934,000 USD 20%
Operating Income (Loss) $112,269,000 USD -12%
Nonoperating Income (Expense) $15,062,000 USD -0.73%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $97,207,000 USD -14%
Earnings Per Share, Basic -1 USD/shares -7%
Earnings Per Share, Diluted -1 USD/shares -7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $101,732,000 USD 1.1%
Marketable Securities, Current $375,833,000 USD 97%
Cash, Cash Equivalents, and Short-term Investments $477,600,000 USD 64%
Assets, Current $482,683,000 USD 63%
Property, Plant and Equipment, Net $399,000 USD -27%
Operating Lease, Right-of-Use Asset $475,000 USD 486%
Other Assets, Noncurrent $7,101,000 USD -1.9%
Assets $490,875,000 USD 61%
Accounts Payable, Current $1,429,000 USD 40%
Liabilities, Current $14,650,000 USD -14%
Operating Lease, Liability, Noncurrent $103,000 USD
Other Liabilities, Noncurrent $103,000 USD
Liabilities $14,753,000 USD -13%
Accumulated Other Comprehensive Income (Loss), Net of Tax $221,000 USD -8.7%
Retained Earnings (Accumulated Deficit) $317,499,000 USD -44%
Stockholders' Equity Attributable to Parent $476,122,000 USD 65%
Liabilities and Equity $490,875,000 USD 61%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $24,127,000 USD -3.3%
Net Cash Provided by (Used in) Financing Activities $234,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $1,427,000 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 59,261,286 shares 25%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $101,732,000 USD 1%
Deferred Tax Assets, Valuation Allowance $63,712,000 USD 49%
Deferred Tax Assets, Gross $63,747,000 USD 48%
Operating Lease, Liability $490,000 USD 476%
Depreciation $74,000 USD -6.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $97,228,000 USD -15%
Lessee, Operating Lease, Liability, to be Paid $514,000 USD 505%
Property, Plant and Equipment, Gross $1,535,000 USD 5.4%
Operating Lease, Liability, Current $387,000 USD 355%
Lessee, Operating Lease, Liability, to be Paid, Year One $414,000 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $24,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $24,590,000 USD 25%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $33,455,000 USD 4.1%
Operating Lease, Payments $100,000 USD 16%
Additional Paid in Capital $793,341,000 USD 56%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $279,000 USD -12%
Share-based Payment Arrangement, Expense $27,047,000 USD 51%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%